Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025)

Innate Pharma (IPHA) has reported Other Non-Current Assets for 9 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.

• Quarterly Other Non-Current Assets rose 64.7% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 64.7% YoY) and the FY2025 annual result came in at $1.1 million, up 64.7% from the prior year.
• Other Non-Current Assets advanced to $1.1 million in Q4 2025 per IPHA's latest filing, from $656599.6 in the prior quarter.
• Over the last five years, Other Non-Current Assets for IPHA reached as high as $1.1 million in Q4 2025 and fell as low as $96726.1 in Q2 2024.
• A 5-year average of $342865.6 and a median of $169555.2 in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets plunged 99.83% — and 2025, when it soared 578.82%.
• Year by year, Other Non-Current Assets stood at $168417.2 in 2021, then climbed by 0.68% to $169555.2 in 2022, then plunged by 41.61% to $99002.0 in 2023, then jumped by 560.92% to $654323.7 in 2024, then surged by 64.7% to $1.1 million in 2025.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.1 million, $656599.6, and $654323.7 for Q4 2025, Q2 2025, and Q4 2024 respectively.